Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for XRCC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | XRCC2 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for biochemical screening and binding assays. |
View XRCC2 Products |
| Gene Delivery | XRCC2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for DNA repair and synthetic lethality assays. |
View XRCC2 Products |
| Benchmark Ab | Anti-XRCC2 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View XRCC2 Products |
| Validator | XRCC2 siRNA Set For knockdown verification in functional DNA damage response assays. |
View XRCC2 Products |
| Related Target A | RAD51 Direct functional binding partner of XRCC2 in homologous recombination. Essential for sub-complex formation assays. |
View RAD51 Products |
| Related Target B | PARP1 Synthetic lethal partner. Crucial for combination screening and resistance bypass evaluation. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex stability and native folding | Mammalian and E. coli expression systems optimized for structural integrity and theoretical MW verification. |
| Subfamily and partner cross-screening | Homolog and partner panel proteins (RAD51, RAD51D) strictly verified by mass spectrometry and SDS-PAGE. |
| Lack of reliable positive controls | Sequence-verified biosimilar and benchmark antibodies included for assay standardization. |
| Off-target and false positive mitigation | Sequence-specific siRNA sets included for target-specific knockdown validation. |
Live XRCC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for XRCC2 therapeutics is intensifying, with major players shifting focus from traditional DNA damaging agents to targeted small molecule inhibitors exploiting synthetic lethality. As first-generation PARP inhibitors encounter resistance, the next wave of R&D is targeting homologous recombination repair (HRR) components like XRCC2 to overcome resistance and sensitize homologous recombination-proficient (HRP) tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Institutes, Biotech Startups | Breast, Ovarian, and Pancreatic Cancers | Protein-Protein Interaction (PPI) assays (Need high-purity XRCC2 and RAD51D proteins) |
| Combination Therapies (with PARPi) | Global Oncology Pharma | PARP-Inhibitor Resistant Tumors | Synergy validation in stable cell lines (Need XRCC2 Lentivirus and siRNA knockdown) |
| Targeted Gene Therapy / RNAi | Preclinical Stage Biotechs | Refractory Solid Tumors | Specificity verification (Need sequence-verified XRCC2 siRNA and controls) |
Title: XRCC2 Drug Discovery Landscape & Assay Reagents | TarMart Description: Buy high-purity XRCC2 recombinant proteins, biosimilar antibodies, and lentivirus. Analyze clinical trends and synthetic lethality assays with our live tracker. Keywords: XRCC2 recombinant protein, XRCC2 antibody, XRCC2 drug discovery, DNA repair, RAD51 paralog, synthetic lethality.